Lyell Immunopharma, Inc. — Director's Dealing 2022

Oct 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2022-10-10

Reporting Person: Thompson Rahsaan (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-10	Option (right to buy)	$6.91	A	715000	Acquired	2032-10-09	Common Stock (715000)	Direct

Footnotes

F1: 1/4 of the option shares shall vest on September 28, 2023, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.